KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bio-Rad Laboratories (BIO) Operating Expenses (2016 - 2026)

Bio-Rad Laboratories has reported Operating Expenses over the past 18 years, most recently at $275.3 million for Q1 2026.

  • Quarterly Operating Expenses fell 2.48% to $275.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Mar 2026, changed 0.18% year-over-year, with the annual reading at $1.1 billion for FY2025, 0.9% up from the prior year.
  • Operating Expenses was $275.3 million for Q1 2026 at Bio-Rad Laboratories, down from $291.3 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $300.5 million in Q1 2023 and troughed at $244.7 million in Q3 2023.
  • The 5-year median for Operating Expenses is $277.9 million (2022), against an average of $275.2 million.
  • Year-over-year, Operating Expenses decreased 14.52% in 2022 and then rose 19.07% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $278.4 million in 2022, then fell by 2.66% to $271.0 million in 2023, then increased by 4.65% to $283.6 million in 2024, then increased by 2.72% to $291.3 million in 2025, then decreased by 5.49% to $275.3 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Operating Expenses are $275.3 million (Q1 2026), $291.3 million (Q4 2025), and $278.1 million (Q3 2025).